Drugmaker cites insufficient participation in study targeting healthy adults while scrutiny expands across multiple fronts.
By yourNEWS Media Newsroom
Pfizer and its partner BioNTech have discontinued a clinical trial evaluating a COVID-19 vaccine in healthy adults aged 50 to 64, citing an inability to recruit enough participants to generate sufficient data.
According to a Just the News report, the companies notified investigators in a March 30 communication that enrollment had fallen short of the 25,000 to 30,000 participants needed. Reporting by Reuters indicated trial contractors had already been instructed weeks earlier to stop recruitment efforts.
“This study is not ending as a result of any safety or benefit-risk concerns,” Pfizer and BioNTech said, attributing the decision to their “inability to generate relevant post-marketing data” due to lagging participation. The companies stated that the U.S. Food and Drug Administration had been notified of the decision.
The halted study comes as regulatory expectations for COVID-19 vaccines have evolved. Officials at the FDA, including Commissioner Marty Makary and Vinay Prasad of the Center for Biologics Evaluation and Research, have indicated that future approvals for booster shots in individuals under 65 may require placebo-controlled clinical trials, a higher evidentiary threshold than earlier authorizations.
Participation challenges appear to extend beyond Pfizer’s trial. Sources cited by Reuters indicated that Moderna has also faced difficulty enrolling participants for a similar study targeting the same age group, with strict eligibility criteria excluding many potential volunteers.
Data from the Centers for Disease Control and Prevention shows reduced uptake of COVID-19 vaccines, with approximately 18% of adults and lower percentages among children receiving recent doses. Additional reporting notes that public willingness to receive further vaccinations has declined, with a plurality of adults indicating they are unlikely to seek additional shots.
The broader context includes shifting assessments of the pandemic. The World Health Organization declared an end to the global emergency phase in May 2023, contributing to changes in public health strategy and demand.
The development also coincides with ongoing legal proceedings involving Pfizer. A False Claims Act lawsuit filed by whistleblower Brook Jackson alleges that fraudulent data was used in the process of obtaining emergency use authorization for the company’s COVID-19 vaccine. The case, currently before the 5th U.S. Circuit Court of Appeals, is expected to receive a ruling in the near future. In a public statement on X, Jackson wrote, “You can’t certify a lie. So what is an FDA authorization built on fraud?” as seen in this post.
The legal dispute follows actions by former Attorney General Pam Bondi, who had sought to dismiss the case prior to her removal from office.
International scrutiny has also emerged. A report by GBNews cited testimony from Helmut Sterz, a former Pfizer toxicologist, who told a German inquiry that certain safety evaluations—such as carcinogenic risk and reproductive impact—were not fully conducted due to time constraints. Sterz stated that the available data left “no reliable estimates” regarding effects on pregnancy.
Additional disclosures tied to Freedom of Information Act litigation revealed internal documentation listing numerous “adverse events of special interest” reported following authorization.
Public commentary on the halted trial has varied. Jeffrey Tucker wrote in a post that declining participation reflects shifting public sentiment. The Vaccine Research Safety Foundation described falling vaccination rates as indicative of a broader reassessment of perceived risks and benefits.
Other observers have questioned whether the trial’s cancellation may influence regulatory policy. Sociologist Josh Guetzkow wrote in a post that the move could be interpreted as pressure on regulators to reconsider stricter trial requirements.
Despite the halted study, financial markets responded modestly, with shares of Pfizer, Moderna, and BioNTech posting slight gains following the announcement, according to Reuters.
The developments reflect a changing landscape for COVID-19 vaccine research, shaped by evolving regulatory standards, declining participation, and ongoing legal and scientific scrutiny.
Original article
Comments